EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Comparing the Financial Burden of Colorectal Cancer Chemotherapy on Indonesian Healthcare Insurance (JKN) Coverage: A Study in East Kalimantan

Erfan Abdissalam, Rizki Nur Azmi, Bintang Dwi Putra, Afifah Puspa Anggraeni, Aulia Rahman, Muhammad Fahmi Hidayat Firdaus

Journal of Tropical Pharmacy and Chemistry · 01.09.2025 · 9 (2) · 245-255

DOI: 10.30872/jtpc.v9i2.314 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Tropical Pharmacy and Chemistry, online erschienen am 01.09.2025. Verfasst von Erfan Abdissalam und 5 weiteren Autor:innen. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Colorectal cancer (CRC) constitutes a major public health burden in Indonesia. Chemotherapy remains the primary treatment for advanced CRC but creates substantial financial pressure on patients, hospitals, and the National Health Insurance (JKN) system. Although reimbursement is provided through the Indonesia Case Base Groups (INA-CBGs), differences between actual costs and tariff rates have been reported.

Objective

This study assessed the financial burden of chemotherapy for stage III and metastatic CRC and its alignment with JKN reimbursement in a government referral hospital in Kalimantan.

Methods

A retrospective cross-sectional study was conducted at Abdoel Wahab Sjahranie Regional General Hospital, Samarinda, using medical records from January-June 2024. A total of 129 chemotherapy visits were analyzed. Direct medical costs were compared with INA-CBG claims using descriptive statistics and the Mann–Whitney U test.

Results

FOLFIRI was the most frequently administered regimen (71%). The total chemotherapy cost was Rp590,674,630, with a mean of Rp4,578,873 per visit. Pharmaceutical costs accounted for 56.58% of total expenditures. Actual costs were adequately covered by JKN, resulting in a positive variance of Rp1,314,544 per visit.

Conclusion

INA-CBG reimbursement adequately covered CRC chemotherapy costs, although continued evaluation of JKN financing sustainability is warranted.

Zitieren

APA

Abdissalam, E., Azmi, R. N., Putra, B. D., Anggraeni, A. P., Rahman, A., & Firdaus, M. F. H. (2025). Comparing the Financial Burden of Colorectal Cancer Chemotherapy on Indonesian Healthcare Insurance (JKN) Coverage: A Study in East Kalimantan. Journal of Tropical Pharmacy and Chemistry, 9(2), 245-255. https://doi.org/10.30872/jtpc.v9i2.314

Vancouver

Abdissalam E, Azmi RN, Putra BD, Anggraeni AP, Rahman A, Firdaus MFH. Comparing the Financial Burden of Colorectal Cancer Chemotherapy on Indonesian Healthcare Insurance (JKN) Coverage: A Study in East Kalimantan. Journal of Tropical Pharmacy and Chemistry. 2025;9(2):245-255. doi:10.30872/jtpc.v9i2.314

BibTeX
@article{Abdissalam2025,
  author = {Abdissalam, Erfan and Azmi, Rizki Nur and Putra, Bintang Dwi and Anggraeni, Afifah Puspa and Rahman, Aulia and Firdaus, Muhammad Fahmi Hidayat},
  title = {Comparing the Financial Burden of Colorectal Cancer Chemotherapy on Indonesian Healthcare Insurance (JKN) Coverage: A Study in East Kalimantan},
  journal = {Journal of Tropical Pharmacy and Chemistry},
  year = {2025},
  volume = {9},
  number = {2},
  pages = {245--255},
  doi = {10.30872/jtpc.v9i2.314}
}
Kostenlos starten →